In a related press release, lead author Gerald A. Beathard, MD, PhD, of the University of Texas Medical Branch, said, “The dramatic difference in durability between the endovascular fistulas and the ...
"Arteriovenous (AV) Fistula Pipeline 2025"DelveInsight's,“Arteriovenous (AV) Fistula – Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in ...
Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback